ENDP Endo International plc

10.48
0  -1%
Previous Close 10.56
Open 10.67
Price To book 0.87
Market Cap 2.34B
Shares 222,957,000
Volume 5,668,057
Short Ratio 1.60
Av. Daily Volume 9,183,320

SEC filingsSee all SEC filings

  1. 8-K - Current report 17761139
  2. 8-K - Current report 17754829
  3. 8-K - Current report 17751670
  4. 8-K - Current report 17726526
  5. PRE 14A - Other preliminary proxy statements 17706785

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Advisory Committee Meeting March 14, 2017 voted 18 to eight that the benefits of reformulated OPANA ER no longer outweigh its risks.
OPANA ER
Management of pain
Phase 2 trial did not meet endpoint
XIAFLEX
Adhesive Capsulitis (“Frozen Shoulder syndrome”)
Approved October 26, 2015.
BEMA Buprenorphine
Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment for which alternative treatment options are inadequate
CRL issued May 30 2013. Approved March 6 2014.
AVEED (testosterone undecanoate) intramuscular injection
Men diagnosed with hypogonadism
Phase 2b data released November 17, 2016. Met endpoints. Phase 3 planned for 2H 2017.
XIAFLEX
Edematous fibrosclerotic panniculopathy (“cellulite”)